R H Vonderheide

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Immunity 10:673-9. 1999
  2. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
  3. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
  4. ncbi request reprint Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, D540C, Boston, MA 02115, USA
    Vox Sang 80:81-9. 2001
  5. ncbi request reprint CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Oncol 19:791-8. 2001
  6. pmc Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients
    B Maecker
    Department of Adult Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Clin Exp Immunol 141:558-62. 2005
  7. ncbi request reprint Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
    A Trojan
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 02114 Boston, Massachusetts, USA
    Cancer Res 61:4761-5. 2001
  8. ncbi request reprint Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium
    B Maecker
    Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
    Curr Mol Med 1:609-19. 2001
  9. ncbi request reprint From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Trends Immunol 22:516-23. 2001
  10. ncbi request reprint Phase I study of recombinant human CD40 ligand in cancer patients
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:3280-7. 2001

Detail Information

Publications11

  1. ncbi request reprint The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Immunity 10:673-9. 1999
    ..These findings identify hTERT as a potentially important and widely applicable target for anticancer immunotherapeutic strategies...
  2. ncbi request reprint Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 61:8366-70. 2001
    ..These findings support clinical efforts to target the hTERT as a tumor antigen with broad therapeutic potential...
  3. ncbi request reprint Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 7:3343-8. 2001
    ..The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen...
  4. ncbi request reprint Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, D540C, Boston, MA 02115, USA
    Vox Sang 80:81-9. 2001
    ..We are now capable of tracking antigen-specific T cells at a single cell level. This review will analyse recent developments and highlight some important issues that need to be addressed in the future...
  5. ncbi request reprint CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Oncol 19:791-8. 2001
    ....
  6. pmc Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients
    B Maecker
    Department of Adult Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Clin Exp Immunol 141:558-62. 2005
    ..These results suggest that strategies targeting hTERT and CYP1B1 may have to utilize techniques to induce T cell responses from a naive precursor frequency...
  7. ncbi request reprint Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
    A Trojan
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 02114 Boston, Massachusetts, USA
    Cancer Res 61:4761-5. 2001
    ..Most important, CTL cell lines that are generated against these peptides specifically lyse epithelial tumor cells expressing Ep-CAM but not normal hematopoietic or bronchial epithelial cells...
  8. ncbi request reprint Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium
    B Maecker
    Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
    Curr Mol Med 1:609-19. 2001
    ..Basic biological principles of 'reverse immunology' as well as technical advantages and difficulties will be addressed...
  9. ncbi request reprint From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Trends Immunol 22:516-23. 2001
    ..Here, we suggest that, based on these advancements, a new class of tumor Ags can be identified by directly linking cancer genomics to cancer immunology and immunotherapy...
  10. ncbi request reprint Phase I study of recombinant human CD40 ligand in cancer patients
    R H Vonderheide
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:3280-7. 2001
    ....
  11. pmc Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4
    R H Vonderheide
    Center for Blood Research, Dana Farber Cancer Institute, Boston, Massachusetts
    J Cell Biol 125:215-22. 1994
    ..Specificity of integrin binding to Ig-like domains may be regulated by a set of nonconserved residues distinct from the conserved motif...